This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. T. Lázaro, MD; M. T. García-Tejero, MD; S. Díaz-Lobato, MD
Madrid, Spain

Arch Intern Med. 1997;157(4):462.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Mesalamine (5-aminosalicylic acid), which is a component of sulfasalazine, has been used to treat inflammatory bowel diseases.¹ Most adverse pulmonary symptoms caused by treatment with sulfasalazine have been attributed to sulfapyridine.² Therefore, we thought it would be of interest to your readers to report a case involving an adverse pulmonary reaction to mesalamine therapy in a patient with ulcerative colitis.

Report of a Case.

A 60-year-old nonsmoking man was admitted to the hospital for increasing dyspnea, low fever, dry cough, and weight loss. All these symptoms developed 4 weeks after treatment with mesalamine was started for his first episode of ulcerative colitis. A chest x-ray film revealed bilateral interstitial infiltrates. The diffusion of carbon monoxide was 67% of the expected value. Physical examination identified rales in the lower fields. Investigations showed a white blood cell count of 7.9X109/L with 0.13 eosinophils. The erythrocyte sedimentation rate was 133 mm/h, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?